KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Common Equity (2019 - 2025)

GoodRx Holdings' Common Equity history spans 7 years, with the latest figure at $616.3 million for Q4 2025.

  • For Q4 2025, Common Equity fell 14.96% year-over-year to $616.3 million; the TTM value through Dec 2025 reached $616.3 million, down 14.96%, while the annual FY2025 figure was $616.3 million, 14.96% down from the prior year.
  • Common Equity for Q4 2025 was $616.3 million at GoodRx Holdings, up from $600.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $895.4 million in Q2 2023 and bottomed at $600.7 million in Q3 2025.
  • The 5-year median for Common Equity is $774.2 million (2022), against an average of $753.1 million.
  • The largest annual shift saw Common Equity surged 180.29% in 2021 before it fell 25.24% in 2024.
  • A 5-year view of Common Equity shows it stood at $831.7 million in 2021, then fell by 2.03% to $814.8 million in 2022, then dropped by 6.49% to $762.0 million in 2023, then fell by 4.9% to $724.7 million in 2024, then decreased by 14.96% to $616.3 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Common Equity are $616.3 million (Q4 2025), $600.7 million (Q3 2025), and $643.0 million (Q2 2025).